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tissue products and how this applies to cord blood
units. She indicated that peripheral blood stem cells
and cord blood are regulated as biologic cell therapies
under the tissue approach. Implementation of the reg-
ulatory approach is under way, and a period of en-
forcement discretion for unrelated donor cord blood
is ongoing. Cord blood manufacturers currently must
register with the Food and Drug Administration. Fi-
nalizing regulations is currently a Food and Drug
Administration priority. There is a recognized need
for international harmonization of cord blood regula-
tions.
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CORD BLOOD TRANSPLANTATION TO ADULT PATIENTS: A SINGLE-
BANK’S EXPERIENCE
Stevens, C.E., Scaradavou, A., Rubinstein, P. National Cord Blood Pro-
gram of the New York Blood Center
Since 1993, the New York Blood Center has provided cord blood
(CB) grafts to more than 1500 recipients, 421 of whom where adults
(age 16). These patients were treated in 53 US and 26 non-US
Transplant Centers (TCs). Data from 391 (92.9%) are available.
The proportion of adult recipients has grown from 9% in 1995 to
over 30% in 2001-2003. More than 90% (363/391) had leukemia
(41% advanced), lymphoma, or myelodysplasia. No. of patients
aged 16-24, 25-39, and 40: 130, 135, and 125, respectively; there
were 15% African American recipients, 13.3%Hispanic, and 65.6%
Caucasoids, respectively. TNC doses 2.5  107/kg were given to
62%, 25-49  107/kg to 37%, and 5  107/kg to 1.3% of all
recipients. HLA was matched at serological levels for A and B and
at DNA allele level for HLA-DR. Seven TCs have performed 10
CB transplantations each. Neutrophil engraftment was signiﬁcantly
reduced when TNC doses2.5 107/kg and stratiﬁed signiﬁcantly
with HLA mismatch levels. Engraftment was superior with TBI
conditioning compared to no TBI; and regimens including meth-
otrexate associated with reduced engraftment. Overall survival was
30.2% at one year and 23% at ﬁve years post-transplant. Centers
with 10 CB transplantations had better survival (by Cox Regres-
sion analysis) and so did those with better HLA matches, those
without advanced stage leukemia, and those whose conditioning
included ﬂudarabine. The effect of cell dose was not signiﬁcant in
the Cox regression. Patients with good HLA matches (6/6 and 5/6
without rejection mismatches) and those conditioned with regimens
including TBI and ﬂudarabine had excellent survival: 68% at one
year, respectively.
The data indicate that, despite the low graft cell doses, remarkable
improvement in overall survival rate of adults transplanted with
cord blood is possible by improvements in HLA matching and
conditioning regimens.
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UMBILICAL CORD BLOOD TRANSPLANTATION: NOVEL APPROACHES
TOWARD IMPROVING ENGRAFTMENT
Wagner, J.E., Barker, J. Blood and Marrow Transplant Program,
University of Minnesota, Minneapolis, MN.
Cryopreserved umbilical cord blood (UCB) has been investigated
as a potential strategy for augmenting the pool of acceptable donors,
reducing the risks of acute and chronic graft-versus-host disease
(GVHD) and improving survival. Cell dose, however, has clearly
been identiﬁed as a major limitation, often preventing the consid-
eration of UCB for adult recipients. Recipients of 1.7 
105CD34/kg have slow hematopoietic recovery (median 35 days)
and signiﬁcantly lower incidence of engraftment (68% [95% CI,
46-91]). Therefore, strategies for increasing the cell dose, e.g., ex
vivo HSC expansion, transplantation of multiple UCB units, and
co-infusion of healthy haploidentical mesenchymal stem cells
(MSC), are being explored.
Multi-unit UCB transplantation. Twenty-three adult and adoles-
cent patients [median age 24 years (range: 13-53)] with high-risk
hematologic malignancy were transplanted with two partially HLA-
matched UCB units after myeloablative conditioning. The median
total infused dose 3.5  107NC/kg (range 1.1-6.3). All evaluable
patients (n  21) engrafted at a median of 23 days (range 15-41)
with one unit predominating. While there was no association be-
tween nucleated cell dose, CD34 cell dose, or HLA-A,B,DRB1
match and which unit predominated, the winning unit had a higher
CD3 dose. Incidence of severe III-IV acute graft-versus-host
disease (GVHD) was 13% (0-26%), and disease-free survival was
57% (95% CI: 35-79) at 1 year. These data suggest that 1) double
unit UCBT is safe with one unit predominating over time, 2) the
unit that disappears over time may facilitate engraftment of the
winning unit, possibly by immune mediated mechanisms, and 3)
CD3 dose might predict which unit will ultimately engraft long
term. Most importantly, the use of two UCB units extends the
application of this treatment to nearly all adults for whom one unit
would have been insufﬁcient.
Co-Infusion of haploidentical MSC and UCB transplantation. Fifteen
patients [median age 7.5 years (range: 0.2-16)] with high risk leu-
kemia were transplanted with HLA 0-2 antigen mismatched UCB
and haploidentical parental donor MSC after a myeloablative con-
ditioning. No toxicity was observed related to the infusion of MSC.
All treated patients (n  8) had hematopoietic recovery and com-
plete chimerism at a median of 19 days (range: 9-28). Platelet
recovery occurred at a median of 1.7 months (range: 1.2-3.3).
Incidence of grade II-IV acute GVHD was 2 of 8 patients with no
patient having chronic disease. With a median followup of 2.9 years,
6 patients are alive and disease free with two patients dying of
infections on days 53 and 63, respectively. These data suggest that
engraftment, particularly platelet recovery, may be enhanced by the
co-infusion of MSC. Clearly larger patient numbers are required to
conﬁrm these preliminary observations.
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UMBILICAL CORD BLOOD TRANSPLANTATION AFTER A NON-MYELOA-
BLATIVE THERAPY IN HIGH RISK ADULTS
Wagner, J.E., Barker, J. Blood and Marrow Transplant Program,
University of Minnesota, Minneapolis, MN.
Bone marrow transplantation (BMT) in adults is associated with a
high risk of graft-versus-host disease (GVHD), opportunistic infec-
tion and regimen related toxicity. For these reasons, umbilical cord
blood (UCB) after a non myeloablative preparative regimen has
been explored.
Fifty-one adults with advanced hematologic malignancies [median
age 50 years (range 19-60)], ineligible for myeloablative condition-
ing by virtue of advanced age, extensive prior therapy or serious
co-morbidities received UCB transplantation after cyclophospha-
mide 50 mg/kg, ﬂudarabine 200 mg/m2, and 200 cGy TBI. Immu-
nosuppression was with cyclosporine-A to at least day 100 and
mycophenolate mofetil to day 30. Eight patients with no combina-
tion chemotherapy in the 6 months prior to transplant also received
ATG during conditioning. Thirteen patients (25%) received single
UCB units and 38 (75%) received double unit grafts. The median
total infused cell dose was 3.4  107NC/kg (range 1.1-5.7). Units
were predominantly 1-2 antigen HLA mismatched with the recip-
ient. Of 50 evaluable patients, neutrophil recovery occurred at a
median of 8 days (range 5-32). Four patients had failure of donor
derived engraftment with autologous recovery and 1 had late graft
rejection. The cumulative incidence of sustained donor engraftment
Second Annual International UCB Symposium
733BB&MT
was 90% (95%CI: 82-98) with a median chimerism of 100% (range
72-100) by day 100. The cumulative incidences of grade II-IV and
grade III-IV acute GVHD were 61% (95%CI: 14-78) and 27%
(95%CI: 14-40) at day 100, and chronic GVHD was 36% (95%CI:
20-52) at 1 year. TRM was 18% (95%CI: 8-28) at day 180, and
relapse/progressive disease was 31% (95%CI: 17-45) at 1 year.
Regression of relapsed or persistent disease has been seen in pa-
tients with myelodysplasia and intermediate and low grade lym-
phoid malignancies (n  8). The probability of overall and pro-
gression-free survival was 57% (95%CI: 40-73) and 48% (95%CI:
32-63) at 1 year. Notably, day 180 transplant related mortality
(TRM) in patients aged 45 years was 11% (95%CI: 1-21), and in
patients with extensive prior therapy was 25% (95%CI: 6-44).
However, patients with serious co-morbidities pre-transplant had a
high TRM of 45% (95%CI: 20-70) at day 180 (p  0.01). These
data suggest that this regimen is both non-myeloablative and as-
sociated with a high incidence of donor engraftment with low
toxicity. Further, this approach appears to extend access to trans-
plant to many adults who would otherwise be ineligible based on
lack of donor and/or inability to tolerate high-dose conditioning.
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CLINICAL RESULTS IN UMBILICAL CORD BLOOD RECIPIENTS WITH
HEMATOLOGICAL MALIGNANCIES USING MYELOABLATIVE REGIMENS
Takahashi, S. University of Tokyo, Japan.
Unrelated cord blood transplantation (CBT) has now become
more common, but as yet there have been only a few reports on its
outcome in adults. We studied the clinical outcomes of 68 adult
patients with hematological malignancies who received unrelated
CBT and compared with bone marrow transplantation (BMT,
n45) from unrelated donors. All recipients received transplanta-
tions after myeloablative regimens including 12 Gy of TBI be-
tween 1996 and 2003. We analyzed the hematopoietic recovery,
rates of GVHD, risks of TRM and relapse, and DFS using Cox
proportional-hazard regression models. The time from donor-
search to transplantation was signiﬁcantly shorter among CBT
recipients (median 3 months) than BMT recipients (median 11
months). The 6 possible matches between the recipient and the
donor were scored serologically for HLA-A and B and genetically
for DRB1 alleles and the results showed 39 (87 %) matched grafts
in BMT and no complete matches in CBT. Although the number
of leukocytes for CBT was 1 log lower than in BMT, 64 out of 68
(94 percent) cord blood grafts contained more than 2.0  107 cells
per kilogram. Multivariate analysis demonstrated slow neutrophil
and platelet recoveries in CBT compared with BMT. Despite the
higher HLA mismatching rate and less use of immunosuppressive
drugs such as steroids even in recipients affected with acute GVHD
higher than grade II, probability of grades III and IV acute GVHD
was signiﬁcantly lower than among BMT recipients in multivariate
analysis. There were no GVHD-related deaths among CBT recip-
ients, compared with 10 deaths out of 24 among BMT recipi-
ents. On the other hand, There was no signiﬁcant difference
between CBT and BMT recipients in chronic GVHD inci-
dence. Unrelated CBT showed better TRM, relapse and DFS
results compared with BMT. These data strongly suggest that
CBT could be safely and effectively used for adult patients with
hematological malignancies.
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COMPARISON OF UNRELATED CORD BLOOD AND BONE MARROW
TRANSPLANTS IN ADULTS WITH ACUTE LEUKEMIA
Gluckman, E. Eurocord Hospital Saint Louis, Paris, France.
Background. Unrelated cord blood is an alternative to bone
marrow cell transplantation in patients with hematopoietic dis-
eases, mainly in children. The objective of this study was to com-
pare both sources of stem cells to treat adults with acute leukemia
(AL). Patients and Methods. We compared 98 adults with AL
given an HLA-incompatible unrelated cord blood transplants
(UCBT) with 584 HLA-matched unrelated bone marrow trans-
plants (UBMT) performed between 1998 and 2002 and reported to
the Eurocord and European Blood and Marrow Transplant regis-
try. Outcomes were compared using multivariate analysis to adjust
for confounding clinical factors. Results. Recipients of UCBT
were younger (median 24.5 versus 32 years, p0.001), weighed less
(median 58 versus 68 kg, p0.001), and had more advanced disease
at transplant (52% versus 33%, p0.001). All UBMT were HLA-
matched whereas most of UCBT were HLA-incompatible
(p0.0001). The median number of nucleated cord blood cells
infused was 0.23  108/kg compared with 2.9  108/kg nucleated
bone marrow cells (p0.001). Multivariate analysis demon-
strated lower risks of grade II-IV acute graft versus-host disease
(p0.001) after UCBT, however neutrophil recovery was sig-
niﬁcantly delayed (p0.001). Transplantation-related mortality,
relapse, chronic GvHD, and leukemia-free survival were com-
parable between UCBT and UBMT recipients. Conclusion.
These results suggest that UCBT is an alternative treatment for
adults with AL lacking an HLA-matched sibling bone marrow
donor.
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UNRELATED-DONOR CORD BLOOD TRANSPLANTATION IN PATIENTS
WITH CHRONIC MYELOID LEUKEMIA
Sanz, G.F., Moscardó, F., Jiménez, C., Lorenzo, I., Planelles, D.,
Larrea, L., Cervera, J., Benlloch, L., Barragán, E., Senent, L., Cantero,
S., Montesinos, P., Remigia, M.J., Sanz, M.A. Hospital Universitario
La Fe and Centro de Transfusion de la Comunidad Valenciana, Valencia,
Spain.
Despite the promising results with imatinib, allogeneic stem cell
transplantation remains the only proven curative approach for
patients with chronic myeloid leukemia (CML). This study reports
the results of unrelated-donor cord blood transplantation (UD-
CBT) in a series of 20 patients with CML treated in a single
institution. Fourteen were in chronic phase (CP; 8 in CP1 and 6 in
CP2), 2 in accelerated phase and 4 in blast crisis. Median age was
32 years (range, 16-46). Conditioning consisted of thiotepa, busul-
fan, cyclophosphamide and antithymocyte globulin, and GVHD
prophylaxis of cyclosporine and prednisone. HLA match was 5/6 in
7 cases and 4/6 in 13. The median number of nucleated and
CD34 cells infused was 1.8  107/kg (range, 1.2-4.9) and 0.8 
105/kg (range, 0.3-2.2), respectively. Median time to PMN above
0.5  109/L and to platelets above 20  109/L was 22 days (range,
10-52) and 69 days (range, 43-188), and the cumulative incidence
of myeloid and platelet engraftment was 85% and 45%, respec-
tively. Time to myeloid engraftment showed a direct relationship
with the number of CFU-GM (P .009) and CD34 cells (P .02)
infused. Platelet engraftment was faster in patients receiving a
higher number of CFU-GM (P .05), in those transplanted in CP
(P  .04) and in those not developing acute GVHD above grade I
(P  .001). Eight patients developed acute GVHD above grade II,
and 7 of 11 patients at risk had extensive chronic GVHD. With a
median follow-up of 49 months (range, 28-82), the probability of
disease-free survival (DFS) at 3 years was 40% and was related to
age (P  .01) and phase of the disease at transplant (P  .04). The
probability of DFS at 3 years was 60% for patients younger than 31
years and 57% for those transplanted in CP. Six of 8 patients aged
30 years or younger and transplanted in CP remain alive and
disease-free. These data suggest that UD-CBT is an acceptable
alternative for younger patients with CML in CP requiring trans-
plantation and lacking a HLA-matched family or unrelated bone
marrow donor.
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COMPARISON OF UNRELATED CORD BLOOD AND UNRELATED BONE
MARROW TRANSPLANTS FOR ADULTS WITH LEUKEMIA A Collabora-
tive Study: The New York Blood Center National Cord Blood Pro-
gram And The International Bone Marrow Transplant Registry
Laughlin, M.J. Case Western Reserve University, Cleveland, Ohio.
Though little is known regarding the safety and efﬁcacy of
umbilical cord blood (UCB) transplantation in adults, these are
increasingly used in older subjects. We compared the results of
169, 1-antigen mismatched UCB, 83, 1-antigen mismatched and
367, matched bone marrow (BM) transplants in patients age 16-60
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